POST Online Media Lite Edition


Specific pathogen resistant shrimp ready for commercialisation

Staff Writer |
The development of specific pathogen resistant shrimp will address issues facing the Asian market and is ready for the commercialisation phase.

Benchmark, the aquaculture health, nutrition and breeding and genetics business, is pleased to announce that it has developed specific pathogen resistant (SPR) shrimp to address issues facing the Asian market, the largest and fastest growing market for shrimp.

The company will soon commence field trials in the region and will provide an update in due course.

This is a breakthrough development which, combined with our leading market position in the industry, creates a very attractive growth opportunity for Benchmark.

Asia produces more than 2.66m tonnes of vannamei shrimp, worth around $13bn with the total value of the market growing by an average 7 percent per annum.

Diseases, including White Spot (WSSV) and AHPND (previously known as Early Mortality Syndrome – EMS), have each resulted in losses valued at billions of dollars per year for the global shrimp industry.

The Asian shrimp industry alone incurred a loss of $22.5bn from AHPND over the period 2009 to 2016.

What to read next

Tremendous decline of Vietnam shrimp sales to the U.S, Japan and EU
Nova Scotia for The Last-In, First-Out fishery
New shrimp farm to open in Iowa